Year All2024202320222021202020192018201720162015 Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum July 1, 2024 Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders June 3, 2024 Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 May 14, 2024 Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting May 9, 2024 Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology May 1, 2024 Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting April 18, 2024 Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus April 17, 2024 Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma April 8, 2024 Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 1, 2024 Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer March 25, 2024
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum July 1, 2024
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 May 14, 2024
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting May 9, 2024
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology May 1, 2024
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting April 18, 2024
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus April 17, 2024
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma April 8, 2024